# Persistency Study After Hib-CRM (Cross-Reacting Material)197 or Hib-TT (Tetanus Toxoid) Vaccines in Chinese Children

> **NCT02139228** · PHASE3 · COMPLETED · sponsor: **Novartis Vaccines** · enrollment: 426 (actual)

## Conditions studied

- Meningitis, Epiglottitis, Pneumonia, Arthritis Caused by Haemophilus Influenzae Type b

## Interventions

- **BIOLOGICAL:** Hib-CRM197
- **BIOLOGICAL:** Hib-TT

## Key facts

- **NCT ID:** NCT02139228
- **Lead sponsor:** Novartis Vaccines
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-11
- **Primary completion:** 2014-12
- **Final completion:** 2015-01
- **Target enrollment:** 426 (ACTUAL)
- **Last updated:** 2015-11-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02139228

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02139228, "Persistency Study After Hib-CRM (Cross-Reacting Material)197 or Hib-TT (Tetanus Toxoid) Vaccines in Chinese Children". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT02139228. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*